CGTLive®’s Weekly Rewind – August 2, 2024
Review top news and interview highlights from the week ending August 2, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Pfizer Drops Development of DMD Gene Therapy Fordadistrogene Movaparvovec
The program’s cancellation follows a previous announcement that its phase 3 trial had missed its primary end point.
2. Joshua M. Hare, MD, on Promising Data on Lomecel-B for Alzheimer Disease
The cofounder and chief science officer of Longeveron discussed updated data from the phase 2a CLEAR MIND study.
3. New Study Recommends Shorter, Flexible Monitoring After CAR T-Cell Therapy
There were no new cases of CRS past 2 weeks after infusion and non-relapse mortality was driven by infection in follow-up.
4. Chris Wright, MD, PhD, on Anelloviruses, a Potential Alternative to AAV for Gene Therapy
The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.
5. Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies
The trial will be open to patients with relapsed/refractory large-B-cell lymphoma and chronic lymphocytic leukemia.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
